Background and Aims: In 2017, Miravitlles and Anzueto demonstrated 'a new two-step algorithm for the treatment of COPD'. This is a simple treatment algorithm based on the severity of symptoms and phenotypes or treatable traits. In this, patient specialized assessment targetting eosinophilic inflammation, chronic bronchitis, and frequent infections, is recommended after exacerbation or deterioration in symptoms occurs despite bronchodilation therapy. However, recent studies have revealed the clinical characteristics of patients who should be added second controllers such as ICS. We consider treatable traits should be assessed and intervened as early as possible. Moreover, the algorithm is necessary to be adapted to the situation of clinical practice, taking into account the patients' characteristics.
Background and Aims: In 2017, Miravitlles and Anzueto demonstrated 'a new two-step algorithm for the treatment of COPD'. This is a simple treatment algorithm based on the severity of symptoms and phenotypes or treatable traits. In this, patient specialized assessment targetting eosinophilic inflammation, chronic bronchitis, and frequent infections, is recommended after exacerbation or deterioration in symptoms occurs despite bronchodilation therapy. However, recent studies have revealed the clinical characteristics of patients who should be added second controllers such as ICS. We consider treatable traits should be assessed and intervened as early as possible. Moreover, the algorithm is necessary to be adapted to the situation of clinical practice, taking into account the patients' characteristics.
Methods:
We propose 'a parallel two-step algorithm' based on the evidence of recent studies.
Results: Once the diagnosis of COPD, The first decision is to divide into two targets parallelly based on the common target for all patients with COPD (Algorithm 1) and the individual target for patients with concomitant disease (Algorithm 2). In Algorithm 1, the initial assessment should be based on the level of dyspnea and the frequency of exacerbations. After the initial assessment, patients with a mMRC score 0-1 or one exacerbation during the previous year may start treatment with a mono-bronchodilator, whereas patients with either a mMRC score ≥2 or with more than one exacerbation in the previous year should start with a dualbronchodilator.
In Algorithm 2, the initial assessment should be based on the asthma characteristics, chronic bronchitis, and frequent infections. After the initial assessment, patients with asthmatic characteristics may consider treatment with ICS, while patients with chronic bronchitis may consider treatment with theophylline and/or roflumilast, while patients with frequent infections may consider treatment with macrolides and/or mucolytics.
Conclusion: This proposal might be considered as an approach based on personalized therapy and useful to the development of COPD management. This study aimed to evaluate the effectiveness of pharmaceutical care on DRPs and clinical outcomes.
Methods: The quasi study was carried out in outpatients of PaknumChumphon Hospital from April, 2017 to April, 2018. Adult diagnosed COPD patients which attending the COPD clinic more than six months were included in the study. All patients were assessed for medication and clinical outcomes before and after 6 months of pharmaceutical care interventions. Relevant data were gathered and analyzed using a paired t-test, χ 2 test and logistic regression analysis (α = 0.05).
Results: Total 120 patients were assessed. The majority of patients were male (66.7%) with the mean age of 67.7 years (SD = 12.3). After interventions, the number of DRPs was decreased from 134 to 36 (73.13%). Most DRPs before the interventions were inappropriate inhaler technique (29.2%) and inappropriate drug selection (19.2%) which were decreased to 14.2% and 3.3% respectively. The factors associated with DRPs including COPD type, exacerbation, COPD Assessment Test (CAT) score and dyspnea score were assessed. The predicted factor for DRPs was CAT score > 10 with OR 11.1 [95% CI 1.02-12.5]. The significant of clinical outcomes improvement were found in force expiratory in one second (FEV 1 ) (67.47% vs 70.31%, P = 0.001), peak expiratory flow rate (PEFR) (62.83% vs 66.54%, P = 0.001), targeted dyspnea score 0-1 (70.2% vs 84.3%, P = 0.012), CAT score < 10 (66.1% vs 86.0%, P = 0.001), COPD type A and B (47.5% vs 72.5%, P = 0.001) and also significantly decreased the exacerbation and hospitalization rate.
Conclusion:
DRPs in COPD patients associated with many factors and could predicted with CAT score > 10. Pharmaceutical care could resolve DRPs and revealed the effectiveness by enable COPD patients to achieve the desired therapeutic outcomes. 
